Stocklytics Platform
Asset logo for symbol INVA
Innoviva
INVA57
$18.99arrow_drop_down1.04%-$0.20
Asset logo for symbol INVA
INVA57

$18.99

arrow_drop_down1.04%

Performance History

Chart placeholder
Key Stats
Open$19.20
Prev. Close$19.17
EPS0.80
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range18.87
19.27
52 Week Range12.22
21.22
Ratios
EPS0.80

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Innoviva (INVA)

Innoviva Inc (INVA) is a pharmaceutical company that focuses on the development and commercialization of innovative respiratory medicines. The company's stock price history shows a steady growth over the years, with occasional fluctuations due to market conditions. Investors can benefit from studying the historical trends and patterns to make informed decisions about the stock. The current quote for INVA reflects its market value at a specific point in time. It is important to monitor the stock news regularly to stay updated on any significant developments that may affect the company's performance.
A comprehensive stock analysis of INVA can provide valuable insights for investors. This analysis includes evaluating the company's financial health, its competitive position in the industry, and the potential for growth. Additionally, it is essential to consider the market cap of INVA, which indicates the overall value of the company's outstanding shares. The PEG ratio is another useful metric that compares the company's earnings growth to its stock valuation, providing an indication of whether the stock is overvalued or undervalued.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Burlingame
Employees
101
Exchange
NASDAQ
add Innoviva  to watchlist

Keep an eye on Innoviva

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Innoviva (INVA)?

Innoviva (INVA) has a market capitalization of $1.19B. The average daily trading volume is 19.05, indicating the stock's liquidity and investor engagement.
help

What is Innoviva 's (INVA) price per share?

The current price per share for Innoviva (INVA) is $19. The stock has seen a price change of -$0.2 recently, indicating a -1.04% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Innoviva (INVA)?

For Innoviva (INVA), the 52-week high is $21.23, which is 11.74% from the current price. The 52-week low is $12.22, the current price is 55.44% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Innoviva (INVA) a growth stock?

Innoviva (INVA) has shown an average price growth of -2.59% over the past three years. It has received a score of 57 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Innoviva as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Innoviva (INVA) stock price performance year to date (YTD)?

As of the latest data, Innoviva (INVA) has a year-to-date price change of 16.04%. Over the past month, the stock has experienced a price change of -5.59%. Over the last three months, the change has been -1.38%. Over the past six months, the figure is 19.17%. Looking at a longer horizon, the five-year price change stands at 42.82%.
help

Is Innoviva (INVA) a profitable company?

Innoviva (INVA) has a net income of $179.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.09% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 48.31% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $310.46M, although specific revenue growth data is currently not available. The gross profit is $261.06M. Operating income is noted at $176.71M. Furthermore, the EBITDA is $168.02M.

Take Your Investments to a Whole New Level